CU20200028A7 - VIRAL NUCLEOPROTEIN AND FORMULATIONS CONTAINING IT - Google Patents
VIRAL NUCLEOPROTEIN AND FORMULATIONS CONTAINING ITInfo
- Publication number
- CU20200028A7 CU20200028A7 CU2020000028A CU20200028A CU20200028A7 CU 20200028 A7 CU20200028 A7 CU 20200028A7 CU 2020000028 A CU2020000028 A CU 2020000028A CU 20200028 A CU20200028 A CU 20200028A CU 20200028 A7 CU20200028 A7 CU 20200028A7
- Authority
- CU
- Cuba
- Prior art keywords
- nucleoprotein
- rna
- infectious
- mass
- innate immunity
- Prior art date
Links
- 102000011931 Nucleoproteins Human genes 0.000 title abstract 4
- 108010061100 Nucleoproteins Proteins 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000003612 virological effect Effects 0.000 title abstract 2
- 229920002477 rna polymer Polymers 0.000 abstract 4
- 230000015788 innate immune response Effects 0.000 abstract 2
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 abstract 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 abstract 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 abstract 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 abstract 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 abstract 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 abstract 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 abstract 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 abstract 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 abstract 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 230000003266 anti-allergic effect Effects 0.000 abstract 1
- 230000002924 anti-infective effect Effects 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24223—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
<p>Nucleoproteína que comprende ácido ribonucleico (ARN) y una proteína de origen viral donde el contenido de ARN es mayor del 20 porciento (masa:masa) y dicho ARN se encuentra protegido de la degradación dentro de una estructura semejante a virus, y donde dicha nucleoproteína activa simultáneamente los receptores de la inmunidad innata TLR3, TLR2, TLR7, TLR8 y TLR9, por lo que potencia una respuesta anti-infecciosa, anti-tumoral o anti-alérgica, o activa y entrena la inmunidad innata en la prevención o tratamiento de procesos infecciosos o alérgicos. Esta nucleoproteína se puede combinarse con otros fármacos y puede aparecer como un adyuvante o un <em>carrier</em> de antígenos vacunales,en formulaciones y en un kit para su administración mucosal.</p><p> Nucleoprotein comprising ribonucleic acid (RNA) and a protein of viral origin where the RNA content is greater than 20 percent (mass: mass) and said RNA is protected from degradation within a virus-like structure, and where said nucleoprotein simultaneously activates the innate immunity receptors TLR3, TLR2, TLR7, TLR8 and TLR9, thereby enhancing an anti-infectious, anti-tumor or anti-allergic response, or activates and trains innate immunity in the prevention or treatment of infectious or allergic processes. This nucleoprotein can be combined with other drugs and can appear as an adjuvant or a <em> carrier </em> of vaccine antigens, in formulations and in a kit for mucosal administration. </p>
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2020000028A CU20200028A7 (en) | 2020-04-20 | 2020-04-20 | VIRAL NUCLEOPROTEIN AND FORMULATIONS CONTAINING IT |
CN202180043563.7A CN115697394A (en) | 2020-04-20 | 2021-04-16 | Viral nucleoproteins and formulations comprising the same |
MX2022013148A MX2022013148A (en) | 2020-04-20 | 2021-04-16 | Viral nucleoprotein and formulations containing same. |
PCT/CU2021/050002 WO2021213558A2 (en) | 2020-04-20 | 2021-04-16 | Viral nucleoprotein and formulations containing same |
JP2022563491A JP2023522118A (en) | 2020-04-20 | 2021-04-16 | Viral nucleoprotein and preparation thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2020000028A CU20200028A7 (en) | 2020-04-20 | 2020-04-20 | VIRAL NUCLEOPROTEIN AND FORMULATIONS CONTAINING IT |
Publications (1)
Publication Number | Publication Date |
---|---|
CU20200028A7 true CU20200028A7 (en) | 2021-11-04 |
Family
ID=77338444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2020000028A CU20200028A7 (en) | 2020-04-20 | 2020-04-20 | VIRAL NUCLEOPROTEIN AND FORMULATIONS CONTAINING IT |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP2023522118A (en) |
CN (1) | CN115697394A (en) |
CU (1) | CU20200028A7 (en) |
MX (1) | MX2022013148A (en) |
WO (1) | WO2021213558A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB202204803D0 (en) * | 2022-04-01 | 2022-05-18 | Univ Manchester | Virus-like particles |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1450856B1 (en) * | 2001-09-14 | 2009-11-11 | Cytos Biotechnology AG | Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use |
WO2011057267A1 (en) * | 2009-11-09 | 2011-05-12 | National Jewish Health | Vaccine composition |
ES2965709T3 (en) | 2016-03-31 | 2024-04-16 | Ct Ingenieria Genetica Biotecnologia | Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis B virus |
-
2020
- 2020-04-20 CU CU2020000028A patent/CU20200028A7/en unknown
-
2021
- 2021-04-16 WO PCT/CU2021/050002 patent/WO2021213558A2/en active Application Filing
- 2021-04-16 CN CN202180043563.7A patent/CN115697394A/en active Pending
- 2021-04-16 MX MX2022013148A patent/MX2022013148A/en unknown
- 2021-04-16 JP JP2022563491A patent/JP2023522118A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021213558A3 (en) | 2021-12-30 |
CN115697394A (en) | 2023-02-03 |
WO2021213558A2 (en) | 2021-10-28 |
MX2022013148A (en) | 2022-11-16 |
JP2023522118A (en) | 2023-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022015132A (en) | Nucleic acid based combination vaccines. | |
ES2731899T3 (en) | Composition of nasal flu vaccine | |
Paul et al. | Immunostimulatory properties of Toll-like receptor ligands in chickens | |
ES2293923T3 (en) | INTRANASAL VACCINE AGAINST THE INFLUENZA VIRUS. | |
ES2562456T3 (en) | Use of an adjuvant that induces a Th1 immune response to improve immune responses | |
JP5809560B2 (en) | Vaccine composition for use against influenza | |
CO2020011914A2 (en) | Self-Assembling Nanostructure Vaccines | |
CA2632516C (en) | Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants | |
KR102141887B1 (en) | Immunogenic compositions comprising silicified virus and methods of use | |
CO6531435A2 (en) | NEW FORMULATIONS OF VACCINE THAT INCLUDES ADJUVANTS CONTAINING SAPONINA | |
ES2340163T3 (en) | VIROSOMAS SIMILAR PARTICLES. | |
AR109538A1 (en) | VACCINE AGAINST THE SWINE FLU | |
Chen et al. | Modulatory effect of CpG oligodeoxynucleotide on a DNA vaccine against nervous necrosis virus in orange-spotted grouper (Epinephelus coioides) | |
CU20200028A7 (en) | VIRAL NUCLEOPROTEIN AND FORMULATIONS CONTAINING IT | |
CO6460752A2 (en) | IMMUNE RESPONSE REINFORCED IN AVIAN SPECIES | |
Avunje et al. | Poly (I: C) and imiquimod induced immune responses and their effects on the survival of olive flounder (Paralichthys olivaceus) from viral haemorrhagic septicaemia | |
Jiang et al. | Role of extracellular vesicles in influenza virus infection | |
AR101814A1 (en) | VIRUS FLAVIVIRUS TYPE PARTICLE | |
Chand et al. | Polyphosphazenes as adjuvants for animal vaccines and other medical applications | |
CL2021003211A1 (en) | A modified live strain of porcine reproductive and respiratory syndrome virus (prrs), a vaccine comprising it and its use to treat prrs type ii. (divisional application no. 2123-2018) | |
CU20200009A7 (en) | COMPOSITIONS TO TREAT AND / OR PREVENT INFECTION BY THE HEPATITIS B VIRUS | |
CN106924282B (en) | Application of the polyetherimide in the drug for preparing flu-prevention virus infection | |
US20230226172A1 (en) | Inactivation of Genome Enveloped within Coronavirus Spherical or Pleomorphic Particles or Shells to Form a Vaccine | |
CU23420A1 (en) | PROTEOLIPOSOMAS AND ITS DERIVATIVES AS INDUCTING ASSISTANTS OF CYTOTOXIC RESPONSE AND THE RESULTING FORMULATIONS | |
ECSP22064620A (en) | RECOMBINANT LIVE IMMUNOGENIC COMPOSITION COMPRISING THE NEWCASTLE DISEASE VIRUS (NDV) EXPRESSING THE S1 SUBUNIT AND THE RBD OF THE SARS-CoV-2 SPIKE PROTEIN |